U.S. markets closed
  • S&P 500

    3,269.96
    -40.15 (-1.21%)
     
  • Dow 30

    26,501.60
    -157.51 (-0.59%)
     
  • Nasdaq

    10,911.59
    -274.00 (-2.45%)
     
  • Russell 2000

    1,538.48
    -23.10 (-1.48%)
     
  • Crude Oil

    35.72
    -0.45 (-1.24%)
     
  • Gold

    1,878.80
    +10.80 (+0.58%)
     
  • Silver

    23.72
    +0.35 (+1.52%)
     
  • EUR/USD

    1.1650
    -0.0029 (-0.24%)
     
  • 10-Yr Bond

    0.8600
    +0.0250 (+2.99%)
     
  • GBP/USD

    1.2951
    +0.0028 (+0.22%)
     
  • USD/JPY

    104.6200
    +0.0100 (+0.01%)
     
  • BTC-USD

    13,850.19
    +59.31 (+0.43%)
     
  • CMC Crypto 200

    265.42
    +1.78 (+0.68%)
     
  • FTSE 100

    5,577.27
    -4.48 (-0.08%)
     
  • Nikkei 225

    22,977.13
    -354.81 (-1.52%)
     

CLASS ACTION UPDATE for PT, STAA and BMRN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·4 mins read

NEW YORK, NY / ACCESSWIRE / October 1, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

PT Shareholders Click Here: https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=9748&wire=1
STAA Shareholders Click Here: https://www.zlk.com/pslra-1/staar-surgical-company-information-request-form?prid=9748&wire=1
BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=9748&wire=1

* ADDITIONAL INFORMATION BELOW *

Pintec Technology Holdings Limited (NASDAQ:PT)

This lawsuit is on behalf of shareholders who purchased PT securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company’s October 2018 initial public offering.
Lead Plaintiff Deadline: November 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=9748&wire=1

According to the filed complaint, (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec’s internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company’s financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Staar Surgical Company (NASDAQ:STAA)

STAA Lawsuit on behalf of: investors who purchased February 26, 2020 - August 10, 2020
Lead Plaintiff Deadline: October 19, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/staar-surgical-company-information-request-form?prid=9748&wire=1

According to the filed complaint, during the class period, Staar Surgical Company made materially false and/or misleading statements and/or failed to disclose that: the Company was overstating and/or mischaracterizing: (1) its sales and growth in China; (2) its marketing spend; (3) its research and development expenses; and that as a result of the foregoing, (4) Defendants’ public statements were materially false and misleading at all relevant times.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

BMRN Lawsuit on behalf of: investors who purchased February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline: November 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=9748&wire=1

According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
http://www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/608821/CLASS-ACTION-UPDATE-for-PT-STAA-and-BMRN-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders